ACTH: What Your Number Changes About Your Treatment

ACTH (adrenocorticotropic hormone) is a peptide hormone made by the anterior pituitary gland. It is not the same molecule as cortisol, and it is not a hormone therapy itself (it is the signal, not the drug). ACTH testing is used clinically to work up suspected adrenal insufficiency and Cushing syndrome, and synthetic ACTH (cosyntropin, brand name Cortrosyn) is FDA-approved as a diagnostic agent for adrenal stimulation testing, not as an ongoing treatment.

The useful question is not "is my ACTH high or low" but "what does my ACTH look like next to my cortisol at the same moment." A single ACTH number means very little on its own. Paired with a same-draw cortisol level, the pattern tells a clinician whether a cortisol problem originates in the adrenal glands or in the pituitary, and that distinction is what decides whether treatment includes one replacement hormone or two, and whether the next test is an adrenal CT or a pituitary MRI. This article explains how that pairing works and where the evidence is solid, where it is guideline-based judgment, and where a precise-sounding number needs verification before anyone acts on it.

The core answer, with its boundary

A morning ACTH above the reference range with a low simultaneous cortisol indicates primary adrenal insufficiency, and this combination is the diagnostic pattern used by endocrinology guidelines to distinguish it from other causes of low cortisol. A low ACTH with a low cortisol instead points to secondary adrenal insufficiency, most often from prior or current glucocorticoid exposure or pituitary disease, and it changes treatment because these patients typically do not need mineralocorticoid replacement. A low ACTH with a high cortisol suggests an ACTH-independent (adrenal) source of excess cortisol rather than a pituitary-driven one. None of these patterns is diagnostic in isolation from timing, assay, and recent medication history, and confirmatory testing (usually a cosyntropin stimulation test) is standard practice before starting lifelong replacement therapy.

What the test actually measures, and why timing matters

ACTH is released in a strong circadian pattern, generally rising overnight to peak in the early morning and falling to its lowest point around midnight. Because of this, a given ACTH value can be normal at 8:00 AM and abnormal at 11:00 PM. Most reference laboratories draw morning ACTH between 7:00 and 9:00 AM and quote a normal range in the neighborhood of 10 to 60 pg/mL, but the exact cutoffs vary by assay and lab, so the reference range printed on your own report is the one that applies to you.

ACTH is also a fragile analyte. Standard practice is to draw the sample into a chilled tube, keep it on ice, and process it quickly, because delayed handling can produce falsely low readings. A single low ACTH drawn under non-ideal conditions is a reason to repeat the test, not a reason to conclude the pituitary has failed.

ACTH is read together with a same-draw cortisol, and often with a cosyntropin stimulation test, because the ratio between the two hormones (not either number alone) is what separates a pituitary-driven problem from an adrenal-driven one.

Factors that shift ACTH independent of disease

Several situations move ACTH without indicating primary pituitary or adrenal disease, and a clinician should account for these before treating a single number as a diagnosis:

• Acute illness, surgery, or physical stress can transiently raise ACTH.
• Any exogenous glucocorticoid (oral, inhaled, topical, or injected) suppresses ACTH through negative feedback on the pituitary. This includes doses many patients do not think of as "steroids," such as long-term high-potency topical steroids over large body-surface areas.
• Chronic opioid therapy is well documented to suppress the hypothalamic-pituitary-adrenal (HPA) axis in a meaningful subset of long-term users, though the exact proportion affected varies across studies and should not be quoted as a fixed figure.
• Oral estrogen raises cortisol-binding globulin, which can raise total cortisol substantially while free (bioactive) cortisol stays relatively stable. This does not change ACTH directly, but it can change how a clinician interprets a cortisol level or a stimulation test result in a woman on oral estrogen. Transdermal estrogen has less effect on binding globulin.
• Testosterone therapy can lower cortisol-binding globulin, which can lower total cortisol measurements without a true change in free cortisol. This is a reason to be cautious about diagnosing adrenal insufficiency in a man on testosterone replacement based on total cortisol alone.

A practical rule that clinicians commonly apply: if a patient used any glucocorticoid in the prior several weeks, ACTH and cortisol values should not be read at face value until either a washout period has passed or a stimulation test clarifies the picture.

High ACTH, low cortisol: primary adrenal insufficiency

When ACTH is elevated and simultaneous morning cortisol is low, the adrenal cortex itself is failing to respond to the pituitary's signal. This is primary adrenal insufficiency, historically called Addison disease. Because the adrenal cortex makes both cortisol and aldosterone, and both are typically lost when the gland is destroyed, standard treatment is two drugs, not one:

• Hydrocortisone, a glucocorticoid, given in divided daily doses (guidelines commonly describe a range roughly in the teens to mid-20s of milligrams per day, with the largest dose on waking to approximate normal circadian secretion).
• Fludrocortisone, a mineralocorticoid, to replace aldosterone. Without it, patients can develop salt wasting, low blood pressure, and dangerously high potassium.

An important point of guideline judgment: ACTH is not used to fine-tune glucocorticoid dosing. Professional guidance on adrenal insufficiency generally advises against chasing a "normalized" ACTH number, because pushing the glucocorticoid dose higher to suppress ACTH increases metabolic risk (weight gain, glucose intolerance, bone loss) without a clear benefit. Dose adequacy is judged mainly by symptoms, blood pressure, electrolytes, and weight over time, not by how close the ACTH gets to the middle of the reference range. Observational registry data have also raised concern that a meaningful share of primary AI patients end up on hydrocortisone doses above the guideline-recommended range, which has been associated with higher rates of metabolic complications in that kind of observational data; this is a signal to review dosing at follow-up, not an indication to self-adjust.

Low ACTH, high cortisol: an adrenal-driven Cushing workup

The opposite pattern, a suppressed ACTH with confirmed excess cortisol (typically shown by elevated 24-hour urinary free cortisol, an abnormal overnight dexamethasone suppression test, or elevated late-night salivary cortisol), points toward an ACTH-independent source: an adrenal adenoma, adrenal carcinoma, or bilateral adrenal nodular disease. The pituitary senses the cortisol excess and shuts its own ACTH output down.

This pattern changes the imaging and treatment path. Workup moves toward adrenal CT rather than pituitary MRI, and treatment is generally surgical (adrenalectomy) rather than transsphenoidal pituitary surgery.

When ACTH instead sits within a detectable range alongside confirmed hypercortisolism, the working diagnosis becomes ACTH-dependent Cushing syndrome, most often a pituitary corticotroph adenoma (Cushing disease) or, less commonly, an ectopic ACTH-secreting tumor (for example, certain lung or neuroendocrine tumors). Distinguishing a pituitary from an ectopic source when imaging is equivocal is a specialist procedure (inferior petrosal sinus sampling), not something a single ACTH value resolves.

Low ACTH, low cortisol: secondary adrenal insufficiency

This is the pattern most clinicians encounter most often. Both ACTH and cortisol are low. The adrenal glands are structurally capable of making cortisol, but they are not being told to.

The dominant cause in practice is exogenous glucocorticoid exposure: prolonged oral prednisone, injected corticosteroids, or even high-potency topical steroids used extensively can suppress CRH and ACTH secretion through negative feedback. Studies of patients on chronic moderate-dose glucocorticoids have found a substantial proportion with a blunted response to cosyntropin stimulation, though the exact dose threshold and the fraction affected differ across studies and should be treated as approximate rather than exact. Other causes include pituitary tumors, pituitary surgery, traumatic brain injury, and lymphocytic hypophysitis.

The treatment difference from primary AI matters clinically: patients with secondary adrenal insufficiency generally need glucocorticoid replacement only. Fludrocortisone is not routinely required because the renin-angiotensin-aldosterone system, and therefore the adrenal zona glomerulosa's aldosterone output, is usually intact when the problem sits upstream in the pituitary. Hydrocortisone dosing follows a similar general range as in primary AI, sometimes lower when some residual pituitary-adrenal function remains.

Because a low ACTH from pituitary disease rarely travels alone, patients found to have secondary adrenal insufficiency from a pituitary or hypothalamic cause should also be screened for other pituitary hormone deficiencies (thyroid, gonadal, growth hormone, prolactin axes).

How the ACTH pattern changes the prescription, not just the diagnosis

Drug selection. Primary AI (high ACTH) calls for hydrocortisone plus fludrocortisone. Secondary AI (low ACTH) calls for hydrocortisone alone. Some patients who struggle with a multi-dose immediate-release hydrocortisone schedule use prednisolone or a modified-release hydrocortisone formulation instead; a modified-release once-daily formulation is approved in Europe. It is not an FDA-approved product in the United States as of this writing, and any claimed metabolic advantage over standard hydrocortisone comes from small trials that would need to be verified and weighed by a specialist before switching.

Dose titration. Clinicians generally use symptoms (fatigue, nausea, low blood pressure on standing, salt craving) rather than an ACTH level to adjust glucocorticoid dose. Some endocrinologists use "day-curve" cortisol profiles, drawing serum cortisol before and after each hydrocortisone dose, for a more granular picture than a single ACTH draw provides.

Sick-day rules. Patients on glucocorticoid replacement are generally advised to carry an emergency injectable hydrocortisone kit and to double or triple their oral dose during febrile illness or significant physical stress. This applies regardless of the specific ACTH value, but the stakes are highest in primary AI, where an untreated adrenal crisis can be fatal. Published mortality estimates for adrenal crisis vary by cohort and era; the clinically important point is that adrenal crisis is a medical emergency requiring immediate glucocorticoid treatment and, when in doubt, emergency care, not that any single mortality percentage applies to an individual patient.

Monitoring. After a dose is stabilized, a typical follow-up cadence is a clinical check every three to six months, with attention to weight, blood pressure, electrolytes (sodium and potassium in particular), fasting glucose, and bone density screening if glucocorticoid exposure is on the higher end of the replacement range over time.

The confirmatory test: ACTH (cosyntropin) stimulation testing

A single morning ACTH-cortisol pair raises suspicion; a stimulation test is generally what confirms adrenal insufficiency. In the standard-dose test, synthetic ACTH (cosyntropin, 250 mcg) is given intravenously and cortisol is measured before and after (commonly at 30 and 60 minutes). A peak cortisol below a lab-specific cutoff (often quoted around 18 mcg/dL, though newer assays sometimes use a lower cutoff) supports a diagnosis of adrenal insufficiency.

This test has a known limitation: the 250 mcg dose is a large, supraphysiologic amount of ACTH, well above a normal pituitary pulse. In early or partial secondary adrenal insufficiency, the adrenal glands may still respond to this flood of synthetic ACTH even though they are underdriven day to day, which can produce a falsely reassuring result. Some endocrinologists therefore use a low-dose (1 mcg) cosyntropin test instead, on the reasoning that it more closely mimics a physiologic ACTH pulse and may catch milder secondary insufficiency that the standard dose misses. Comparative data on sensitivity and specificity between the two protocols exist but vary across studies, and the standard-dose test remains the one used most widely in routine practice.

The insulin tolerance test, which uses insulin-induced hypoglycemia to provoke a stress cortisol response, is considered by many specialists the most rigorous test of HPA-axis integrity, particularly when growth hormone deficiency is also being evaluated. It is contraindicated in patients with seizure disorders or coronary artery disease and is typically reserved for specialist settings.

ACTH alongside other hormone therapies

Testosterone and estrogen therapy change cortisol-binding globulin levels (as described above) without changing ACTH secretion directly. The practical implication is that a low total cortisol in a man on testosterone, or a high total cortisol in a woman on oral estrogen, may reflect a binding-protein effect rather than a true HPA-axis problem. Clinicians who order cortisol or ACTH-cortisol testing in these patients generally need to interpret the result with the hormone therapy in mind rather than applying a general-population cutoff automatically.

GLP-1 receptor agonists (semaglutide, tirzepatide) have not been flagged in the large obesity and diabetes trial programs as having a clinically meaningful direct interaction with the HPA axis. Weight loss itself can alter cortisol metabolism and clearance, and it is biologically plausible that meaningful weight loss could shift hydrocortisone dose requirements in a patient already on replacement therapy, but this has not been established as a defined, quantified effect in this population, and any dose adjustment in that setting should be individualized by the prescribing clinician rather than made from a general rule.

When to retest, and when this needs a specialist rather than a single lab value

Retesting ACTH has a role in a few defined situations: after pituitary surgery, to track recovery of the axis over months; after tapering long-term exogenous steroids, to confirm the axis has recovered before fully stopping replacement; and in patients with a known pituitary adenoma being watched rather than treated, to screen for progressive hormone loss.

Referral to endocrinology is appropriate when the ACTH-cortisol pattern does not match the clinical picture, when ACTH remains markedly elevated despite what should be adequate replacement, when an ectopic ACTH-secreting tumor is suspected, or when Cushing syndrome is suspected clinically. Anyone who has experienced an adrenal crisis should be referred for specialist management and formal sick-day and emergency-injection education; professional consensus statements emphasize giving this education soon after diagnosis, though the exact timeframe cited for that recommendation should be confirmed against the current guideline before it is stated as a fixed rule to patients.

A persistently high ACTH in a patient already on replacement therapy is a reason to review medication timing, adherence, and absorption with a clinician before assuming the dose itself needs to go up.

Evidence boundary: what is established, what is plausible, what is not established

Established: the ACTH-cortisol pairing (not ACTH alone) is the standard basis for distinguishing primary from secondary adrenal insufficiency and for triggering a Cushing syndrome workup; primary AI requires both glucocorticoid and mineralocorticoid replacement while secondary AI generally requires glucocorticoid alone; cosyntropin stimulation testing is the standard confirmatory step; ACTH is not used to titrate glucocorticoid dose.

Plausible but not firmly quantified for individual dosing decisions: the degree to which weight loss on GLP-1 therapy changes hydrocortisone requirements; the precise proportion of patients on chronic moderate-dose steroids who develop a blunted stimulation response; the comparative real-world advantage of modified-release hydrocortisone over standard dosing for a given patient.

Not established from this evidence base, and requiring verification before being restated as fact: any single fixed percentage for adrenal crisis mortality, for the proportion of opioid users with a suppressed axis, or for the sensitivity and specificity difference between low-dose and standard-dose cosyntropin testing. These figures appear in the literature but vary by study population and era, and a precise number should not be quoted to a patient without checking the current primary source.

Decision framework: reading your own ACTH result

Use this only as a way to understand what your own clinician is likely doing with the number, not as a substitute for a same-draw cortisol and clinical evaluation.

This article is written for general education about how ACTH testing patterns inform treatment decisions. It is not a substitute for individualized diagnosis or dosing guidance from the clinician managing your care, and several of the numeric figures discussed above are cited as general findings from the endocrinology literature that should be checked against current primary sources during medical review before being presented to patients as fixed statistics.